Biogen And Stoke Therapeutics Highlight Urgent Need For New Medicines Targeting Underlying Genetic Cause Of Dravet Syndrome To Improve Long Term Outcomes

Author: Benzinga Newsdesk | November 17, 2025 07:38am

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development –

– Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes

Posted In: BIIB STOK